Surgical Treatments of Tricuspid Valve Regurgitation After Cardiac Surgery

August 13, 2024 updated by: Huanlei Huang, PhD, Guangdong Provincial People's Hospital

Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University

This study aims to present our center's experience in managing postoperative tricuspid valve regurgitation over the past 25years and to analyze the outcomes of these surgical treatments.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

375

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Guangdong
      • Guangzhou, Guangdong, China, 510080
        • Recruiting
        • Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
        • Contact:
        • Sub-Investigator:
          • Yingjie Ke
        • Sub-Investigator:
          • Shuo Xiao
        • Sub-Investigator:
          • Zhaolong Zhang
        • Sub-Investigator:
          • Lishan Zhong
        • Sub-Investigator:
          • Linbin Hua
        • Sub-Investigator:
          • Shanwen Pang
        • Sub-Investigator:
          • Junfei Zhao
        • Sub-Investigator:
          • Qiuji Wang
        • Principal Investigator:
          • Huanlei Huang

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients who underwent surgical treatment from 1999 to 2023 for tricuspid valve disease following cardiac surgery

Description

Inclusion Criteria:patients who underwent surgical treatment from 1999 to 2023 for tricuspid valve disease following cardiac surgery

Exclusion Criteria: age <16，severe tricuspid regurgitation secondary to primary pulmonary hypertension, and those with substantial missing case data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
TVR
tricuspid valve replacement group，
Procedure: Huanlei Huang
tricuspid valve replacement or plasty
TVP
tricuspid valvuloplasty group
Procedure: Huanlei Huang
tricuspid valve replacement or plasty

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
death rate
Time Frame: 1999-01 - 2025-01
perioperative and longterm
1999-01 - 2025-01
complications
Time Frame: 1999-01 - 2025-01
perioperative and longterm complications
1999-01 - 2025-01

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
redo of tricuspid valve
Time Frame: 1999-01 - 2025-01
redo of tricuspid valve during the follow-up
1999-01 - 2025-01

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Guangdong Provincial People's Hospital

Investigators

  • Study Director: Huanlei Huang, Guangdong Provincial People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 1999

Primary Completion (Estimated)

January 1, 2025

Study Completion (Estimated)

January 1, 2025

Study Registration Dates

First Submitted

August 13, 2024

First Submitted That Met QC Criteria

August 13, 2024

First Posted (Actual)

August 15, 2024

Study Record Updates

Last Update Posted (Actual)

August 15, 2024

Last Update Submitted That Met QC Criteria

August 13, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Guangdong Provincial PHosp

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tricuspid Valve Regurgitation; Complications, Longterm Outcome

Clinical Trials on Huanlei Huang

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe